Huwentoxin-IV

Total Page：16

File Type：pdf, Size：1020Kb

Huwentoxin-IV HwTx IV- #08HWT002 Product information Animal toxins for life-sciences TTX-S selective blocker www.smartox-biotech.com Huwentoxin IV (HwTx-IV) is a neurotoxin that was originally isolated from Haplopelma schmidti (Chinese bird spider). This lethal neurotoxin acts selectively on tetrodotoxin- Phone : +33(0) 456 520 869 sensitive (TTX-S) voltage-gated sodium channels, with an IC 50 of 30 nM in rat DRG Fax : +33(0) 456 520 868 [email protected] neurons. It preferentially inhibits neuronal voltage-gated sodium channel subtype hNa v 1.7 (SCN9A, IC 50 is 26 nM), rNa v 1.2 (SCN2A, IC 50 is 150 nM), and rNa v 1.3 (SCN3A, IC Smartox Biotechnology 50 is 338 nM), compared with muscle subtypes rNa v 1.4 (SCN4A) and hNa v 1.5 (SCN5A) 570 rue de la chimie (IC 50 is > 10 µM). Huwentoxin IV inhibits the activation of sodium channels by trapping 38400 Saint Martin d’Hères the voltage sensor of domain II of the site 4 in the inward, closed configuration. France Prices 100 µg – 110 € 500 µg – 330 € 1 mg – 500 € Technical information Related products AA sequence: Glu-Cys2-Leu-Glu-Ile-Phe-Lys-Ala-Cys9-Asn-Pro-Ser-Asn-Asp-Gln-Cys16- 17 24 31 Cys -Lys-Ser-Ser-Lys-Leu-Val-Cys -Ser-Arg-Lys-Thr-Arg-Trp-Cys -Lys-Tyr-Gln-Ile-NH2 2 17 9 24 16 31 Hainantoxin III - #13HTX003 Disulfide bridges: Cys -Cys , Cys -Cys and Cys -Cys Hainantoxin IV - #12HTX001 Length (aa): 35 Solubility: water and saline buffer Huwentoxin-I - #07HWT001 Formula: C174H277N51O52S6 Source: Synthetic GsAF-2 - # 12GSF002 Molecular Weight: 4107.20 Da Purity rate: > 97 % Appearance: White lyophilized solid References Minassian NA., et al.- JBC Xiao Y., et al. - JBC Wang RL., et al. – Jzus Xiao Y., et al. - Mol Pharmacol Peng K., et al. - JBC Peigneur S., et al. - FASEB J. Toxin of the month – free sample program Each month, Smartox Biotechnology offers a sample of a selected toxin for absolutely free. To be informed, visit our website each Ordering information month, subscribe our newsletter or follow us on social networks. Clic HERE Smartox products are available worldwide. To place an order, please contact us by phone or email or find out your local distributor on our website. We accept credit card payment. Range of blockers Voltage-gated sodium channels Acid-sensing ion channels Voltage-gated calcium channels Chloride channels Potassium channels Nicotinic acetylcholine receptors Voltage-gated potassium channels Purinergic receptors Calcium activated potassium channels TRP channels hERG channel Mechanosensitive ion channels Inward rectifying potassium channels NMDA receptors Follow us on All products are intended for research use only and are not intended for diagnostic or therapeutic use, not for use in humans www.smartox - biotech.com About Smartox .

Copy Link

Recommended publications

Tetrodotoxin
Niharika Mandal et al. / Journal of Pharmacy Research 2012,5(7),3567-3570 Review Article Available online through ISSN: 0974-6943 http://jprsolutions.info Tetrodotoxin: An intriguing molecule Niharika Mandal*, Samanta Sekhar Khora, Kanagaraj Mohanapriya, and Soumya Jal School of Biosciences and Technology, VIT University, Vellore-632013 Tamil Nadu, India Received on:07-04-2012; Revised on: 12-05-2012; Accepted on:16-06-2012 ABSTRACT Tetrodotoxin (TTX) is one of the most potent neurotoxin of biological origin. It was first isolated from puffer fish and it has been discovered in various arrays of organism since then. Its origin is still unclear though some reports indicate towards microbial origin. TTX selectively blocks the sodium channel, inhibiting action potential thereby, leading to respiratory paralysis. TTX toxicity is mainly caused due to consumption of puffer fish. No Known antidote for TTX exists. Treatment is symptomatic. The present review is therefore, an effort to give an idea about the distribution, origin, structure, pharmacol- ogy, toxicity, symptoms, treatment, resistance and application of TTX. Key words: Tetrodotoxin, Neurotoxin, Puffer fish. INTRODUCTION One of the most intriguing biotoxins isolated and described in the twentieth cantly more toxic than TTX. Palytoxin and maitotoxin have potencies nearly century is the neurotoxin, Tetrodotoxin (TTX, CAS Number [4368-28-9]). 100 times that of TTX and Saxitoxin, and all four toxins are unusual in being A neurotoxin is a toxin that acts specifically on neurons usually by interact- non-proteins. Interestingly, there is also some evidence for a bacterial bio- ing with membrane proteins and ion channels mostly resulting in paralysis.
[Show full text]
Examples of Successful Protein Expression with SUMO Reference Protein Type Family Kda System (Pubmed ID)
Examples of Successful Protein Expression with SUMO Reference Protein Type Family kDa System (PubMed ID) 23 (FGF23), human Growth factor FGF superfamily ~26 E. coli 22249723 SARS coronavirus (SARS-CoV) membrane 3C-like (3CL) protease Viral membrane protein protein 33.8 E. coli 16211506 5′nucleotidase-related apyrase (5′Nuc) Saliva protein (apyrase) 5′nucleotidase-related proteins 65 E. coli 20351782 Acetyl-CoA carboxylase 1 (ACC1) Cytosolic enzyme Family of five biotin-dependent carboxylases ~7 E. coli 22123817 Acetyl-CoA carboxylase 2 (ACC2) BCCP domain Cytosolic enzyme Family of five biotin-dependent carboxylases ~7 E. coli 22123817 Actinohivin (AH) Lectin Anti-HIV lectin of CBM family 13 12.5 E. coli DTIC Allium sativum leaf agglutinin (ASAL) Sugar-binding protein Mannose-binding lectins 25 E. coli 20100526 Extracellular matrix Anosmin protein Marix protein 100 Mammalian 22898776 Antibacterial peptide CM4 (ABP-CM4) Antibacterial peptide Cecropin family of antimicrobial peptides 3.8 E. coli 19582446 peptide from centipede venoms of Scolopendra Antimicrobial peptide scolopin 1 (AMP-scolopin 1) small cationic peptide subspinipes mutilans 2.6 E. coli 24145284 Antitumor-analgesic Antitumor-analgesic peptide (AGAP) peptide Multifunction scorpion peptide 7 E. coli 20945481 Anti-VEGF165 single-chain variable fragment (scFv) Antibody Small antibody-engineered antibody 30 E. coli 18795288 APRIL TNF receptor ligand tumor necrosis factor (TNF) ligand 16 E. coli 24412409 APRIL (A proliferation-inducing ligand, also named TALL- Type II transmembrane 2, TRDL-1 and TNFSF-13a) protein Tumor necrosis factor (TNF) family 27.51 E. coli 22387304 Aprotinin/Basic pancreatic trypsin inhibitor (BPTI) Inhibitor Kunitz-type inhibitor 6.5 E.
[Show full text]
Zetekitoxin AB
Zetekitoxin AB Kate Wilkin Laura Graham Background of Zetekitoxin AB Potent water-soluble guanidinium toxin extracted from the skin of the Panamanian golden frog, Atelopus zeteki. Identified by Harry S. Mosher and colleagues at Stanford University, 1969. Originally named 1,2- atelopidtoxin. Progression 1975 – found chiriquitoxin in a Costa Rican Atelopus frog. 1977 – Mosher isolated 2 components of 1,2-atelopidtoxin. AB major component, more toxic C minor component, less toxic 1986 – purified from skin extracts by Daly and Kim. 1990 – the major component was renamed after the frog species zeteki. Classification Structural Identification Structural Identification - IR -1 Cm Functional Groups 1268 OSO3H 1700 Carbamate 1051 – 1022 C – N Structural Identification – MS Structural Identification – 13C Carbon Number Ppm Assignment 2 ~ 159 C = NH 4 ~ 85 Quaternary Carbon 5 ~ 59 Tertiary Carbon 6 ~ 54 Tertiary Carbon 8 ~ 158 C = NH Structural Identification – 13C Carbon Number Ppm Assignment 10 55 / 43 C H2 - more subst. on ZTX 11 89 / 33 Ring and OSO3H on ZTX 12 ~ 98 Carbon attached to 2 OH groups 19 / 13 70 / 64 ZTX: C – N STX: C – C 20 / 14 ~ 157 Carbamate Structural Identification – 13C Carbon Number Ppm Assignment 13 156 Amide 14 34 CH2 15 54 C – N 16 47 Tertiary Carbon 17 69 C – O – N 18 62 C – OH Structural Identification - 1H Synthesis Synthesis O. Iwamoto and Dr. K. Nagasawa Tokyo University of Agriculture and Technology. October 10th, 2007 “Further work to synthesize natural STXs and various derivatives is in progress with the aim of developing isoform-selective sodium-channel inhibitors” Therapeutic Applications Possible anesthetic, but has poor therapeutic index.
[Show full text]
Harmful Algal Blooms Background and Reporting Information
Rev 8-12-2019 Harmful Algal Blooms Background and Reporting Information Harmful Algal Blooms (HABs) Cyanobacteria are a kind of photosynthetic bacteria commonly found in Ohio’s lakes, ponds, and slow- moving rivers. Waters with excess nutrients (phosphorus and nitrogen) caused by pollutants may experience rapid growth in the cyanobacteria populations, leading to visible changes in the water known as “blooms”. Due to the green appearance blooms often give effected waters, cyanobacteria are commonly referred to as “blue-green algae”. Some species of cyanobacteria form Harmful Algal Blooms (HABs), releasing potentially dangerous cyanotoxins in the water. Recognizing a HAB There is no sure way to tell the difference between HABs and harmless blooms. Though commonly green or blue-green, the appearance of HABs vary greatly. Look for unusual colors (green to white to black), textures (film, crusts, puffballs) and patterns (clippings, dots, streaks). Some HABs look like spilled paint, pea soup, foam, wool, streaks or green cottage cheese curds. HABs Can Produce Harmful Toxins, Including Microcystin Cyanobacteria can release many kinds of toxins that cause damage to the liver, nervous system, or skin. Drinking, touching, or accidently breathing in droplets of dirty water can all lead to HAB-related illnesses. Symptoms of HAB-related illness includes diarrhea, vomiting, irritated skin, dizziness, light-headedness Toxin Type of Toxin and allergic Anatoxin-a Neurotoxin reactions. HABs can Anatoxin-a(s) Neurotoxin produce toxic Cylindrospermopsin Hepatotoxin chemicals in the Lyngbyatoxin Dermatoxin form of neurotoxins Microcystin Hepatotoxin (which affect the Saxitoxin Neurotoxin nervous system), hepatotoxins (which affect the liver), and dermatoxins (which affect the skin).
[Show full text]
Animal Venom Derived Toxins Are Novel Analgesics for Treatment Of
Short Communication iMedPub Journals 2018 www.imedpub.com Journal of Molecular Sciences Vol.2 No.1:6 Animal Venom Derived Toxins are Novel Upadhyay RK* Analgesics for Treatment of Arthritis Department of Zoology, DDU Gorakhpur University, Gorakhpur, UP, India Abstract *Corresponding authors: Ravi Kant Upadhyay Present review article explains use of animal venom derived toxins as analgesics of the treatment of chronic pain and inflammation occurs in arthritis. It is a [email protected] progressive degenerative joint disease that put major impact on joint function and quality of life. Patients face prolonged inappropriate inflammatory responses and bone erosion. Longer persistent chronic pain is a complex and debilitating Department of Zoology, DDU Gorakhpur condition associated with a large personal, mental, physical and socioeconomic University, Gorakhpur, UttarPradesh, India. burden. However, for mitigation of inflammation and sever pain in joints synthetic analgesics are used to provide quick relief from pain but they impose many long Tel: 9838448495 term side effects. Venom toxins showed high affinity to voltage gated channels, and pain receptors. These are strong inhibitors of ion channels which enable them as potential therapeutic agents for the treatment of pain. Present article Citation: Upadhyay RK (2018) Animal Venom emphasizes development of a new class of analgesic agents in form of venom Derived Toxins are Novel Analgesics for derived toxins for the treatment of arthritis. Treatment of Arthritis. J Mol Sci. Vol.2 No.1:6 Keywords: Analgesics; Venom toxins; Ion channels; Channel inhibitors; Pain; Inflammation Received: February 04, 2018; Accepted: March 12, 2018; Published: March 19, 2018 Introduction such as the back, spine, and pelvis.
[Show full text]
A Functional Nav1.7-Navab Chimera with a Reconstituted High-Affinity Protx-II Binding Site S
Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/06/23/mol.117.108712.DC1 1521-0111/92/3/310–317$25.00 https://doi.org/10.1124/mol.117.108712 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:310–317, September 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site s Ramkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, Mian Gao, Simon Low, Lisa Megson, David Wensel, Rick L. Pieschl, Debra J. Post-Munson, John Watson, David R. Langley, Michael K. Ahlijanian, Linda J. Bristow, and James Herrington Molecular Discovery Technologies, Wallingford, Connecticut, Princeton, New Jersey, and Waltham, Massachusetts (R.R., S.W., I.R., M.G., S.L., L.M., D.W., D.R.L.); Discovery Biology (R.L.P., D.J.P.-M., M.K.A., L.J.B., J.H.) and Lead Discovery and Optimization (J.W.), Bristol-Myers Squibb Company, Wallingford, Connecticut Downloaded from Received March 6, 2017; accepted June 14, 2017 ABSTRACT The NaV1.7 voltage-gated sodium channel is implicated in part of the voltage sensor domain 2 (VSD2) of NaV1.7. Importantly, human pain perception by genetics. Rare gain of function this chimera, DII S1–S4, forms functional sodium channels and is molpharm.aspetjournals.org mutations in NaV1.7 lead to spontaneous pain in humans whereas potently inhibited by the NaV1.7 VSD2 targeted peptide toxin loss of function mutations results in congenital insensitivity to pain. ProTx-II. Further, we show by [125I]ProTx-II binding and surface Hence, agents that specifically modulate the function of NaV1.7 plasmon resonance that the purified DII S1–S4 protein retains high have the potential to yield novel therapeutics to treat pain.
[Show full text]
Toxicological and Pharmacological Profile of Amanita Muscaria (L.) Lam
Pharmacia 67(4): 317–323 DOI 10.3897/pharmacia.67.e56112 Review Article Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine Maria Voynova1, Aleksandar Shkondrov2, Magdalena Kondeva-Burdina1, Ilina Krasteva2 1 Laboratory of Drug metabolism and drug toxicity, Department “Pharmacology, Pharmacotherapy and Toxicology”, Faculty of Pharmacy, Medical University of Sofia, Bulgaria 2 Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, Bulgaria Corresponding author: Magdalena Kondeva-Burdina ([email protected]) Received 2 July 2020 ♦ Accepted 19 August 2020 ♦ Published 26 November 2020 Citation: Voynova M, Shkondrov A, Kondeva-Burdina M, Krasteva I (2020) Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine. Pharmacia 67(4): 317–323. https://doi.org/10.3897/pharmacia.67. e56112 Abstract Amanita muscaria, commonly known as fly agaric, is a basidiomycete. Its main psychoactive constituents are ibotenic acid and mus- cimol, both involved in ‘pantherina-muscaria’ poisoning syndrome. The rising pharmacological and toxicological interest based on lots of contradictive opinions concerning the use of Amanita muscaria extracts’ neuroprotective role against some neurodegenerative diseases such as Parkinson’s and Alzheimer’s, its potent role in the treatment of cerebral ischaemia and other socially significant health conditions gave the basis for this review. Facts about Amanita muscaria’s morphology, chemical content, toxicological and pharmacological characteristics and usage from ancient times to present-day’s opportunities in modern medicine are presented. Keywords Amanita muscaria, muscimol, ibotenic acid Introduction rica, the genus had an ancestral origin in the Siberian-Be- ringian region in the Tertiary period (Geml et al.
[Show full text]
Amanita Muscaria: Ecology, Chemistry, Myths
Entry Amanita muscaria: Ecology, Chemistry, Myths Quentin Carboué * and Michel Lopez URD Agro-Biotechnologies Industrielles (ABI), CEBB, AgroParisTech, 51110 Pomacle, France; [email protected] * Correspondence: [email protected] Definition: Amanita muscaria is the most emblematic mushroom in the popular representation. It is an ectomycorrhizal fungus endemic to the cold ecosystems of the northern hemisphere. The basidiocarp contains isoxazoles compounds that have specific actions on the central nervous system, including hallucinations. For this reason, it is considered an important entheogenic mushroom in different cultures whose remnants are still visible in some modern-day European traditions. In Siberian civilizations, it has been consumed for religious and recreational purposes for millennia, as it was the only inebriant in this region. Keywords: Amanita muscaria; ibotenic acid; muscimol; muscarine; ethnomycology 1. Introduction Thanks to its peculiar red cap with white spots, Amanita muscaria (L.) Lam. is the most iconic mushroom in modern-day popular culture. In many languages, its vernacular names are fly agaric and fly amanita. Indeed, steeped in a bowl of milk, it was used to Citation: Carboué, Q.; Lopez, M. catch flies in houses for centuries in Europe due to its ability to attract and intoxicate flies. Amanita muscaria: Ecology, Chemistry, Although considered poisonous when ingested fresh, this mushroom has been consumed Myths. Encyclopedia 2021, 1, 905–914. as edible in many different places, such as Italy and Mexico [1]. Many traditional recipes https://doi.org/10.3390/ involving boiling the mushroom—the water containing most of the water-soluble toxic encyclopedia1030069 compounds is then discarded—are available. In Japan, the mushroom is dried, soaked in brine for 12 weeks, and rinsed in successive washings before being eaten [2].
[Show full text]
Swaminathan (Article)
© 2000 Nature America Inc. • http://structbio.nature.com articles Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B Subramanyam Swaminathan and Subramaniam Eswaramoorthy Clostridium botulinum neurotoxins are among the most potent toxins to humans. The crystal structures of intact C. botulinum neurotoxin type B (BoNT/B) and its complex with sialyllactose, determined at 1.8 and 2.6 Å resolution, respectively, provide insight into its catalytic and binding sites. The position of the belt region in BoNT/B is different from that in BoNT/A; this observation presents interesting possibilities for designing specific inhibitors that could be used to block the activity of this neurotoxin. The structures of BoNT/B and its complex with sialyllactose provide a detailed description of the active site and a model for interactions between the toxin and its cell surface receptor. The latter may provide valuable information for recombinant vaccine development. Botulinum and tetanus neurotoxins are solely responsible for the neuroparalytic syndromes of botulism and tetanus. These toxins .com are among the most poisonous known, with LD50 values in humans in the range of 0.1–1 ng kg-1 (ref. 1). Clostridium botu- linum cells produce seven serotypes of botulinum neurotoxin (BoNT, EC 3.4.24.69), called A–G, while tetanus neurotoxin (TeNT, EC 3.4.24.68) is produced by Clostridium tetani. These toxins are all produced as single inactive polypetide chains of ∼150 kDa that are cleaved by tissue proteinases into two chains: a heavy (H) chain of ∼100 kDa and a light (L) chain of ∼50 kDa http://structbio.nature • linked by a single disulfide bond.
[Show full text]
Pain Research Product Guide | Edition 2
Pain Research Product Guide | Edition 2 Chili plant Capsicum annuum A source of Capsaicin Contents by Research Area: • Nociception • Ion Channels • G-Protein-Coupled Receptors • Intracellular Signaling Tocris Product Guide Series Pain Research Contents Page Nociception 3 Ion Channels 4 G-Protein-Coupled Receptors 12 Intracellular Signaling 18 List of Acronyms 21 Related Literature 22 Pain Research Products 23 Further Reading 34 Introduction Pain is a major public health problem with studies suggesting one fifth of the general population in both the USA and Europe are affected by long term pain. The International Association for the Study of Pain (IASP) defines pain as ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Management of chronic pain in the clinic has seen only limited progress in recent decades. Treatment of pain has been reliant on, and is still dominated by two classical medications: opioids and non-steroidal anti-inflammatory drugs (NSAIDs). However, side effects such as dependence associated with opioids and gastric ulceration associated with NSAIDs demonstrates the need for new drug targets and novel compounds that will bring in a new era of pain therapeutics. Pain has been classified into three major types: nociceptive pain, inflammatory pain and neuropathic or pathological pain. Nociceptive pain involves the transduction of painful stimuli by peripheral sensory nerve fibers called nociceptors. Neuropathic pain results from damage or disease affecting the sensory system, and inflammatory pain represents the immunological response to injury through inflammatory mediators that contribute to pain. Our latest pain research guide focuses on nociception and the transduction of pain to the spinal cord, examining some of the main classical targets as well as emerging pain targets.
[Show full text]
A Review of Chemical Defense in Poison Frogs (Dendrobatidae): Ecology, Pharmacokinetics, and Autoresistance
Chapter 21 A Review of Chemical Defense in Poison Frogs (Dendrobatidae): Ecology, Pharmacokinetics, and Autoresistance Juan C. Santos , Rebecca D. Tarvin , and Lauren A. O’Connell 21.1 Introduction Chemical defense has evolved multiple times in nearly every major group of life, from snakes and insects to bacteria and plants (Mebs 2002 ). However, among land vertebrates, chemical defenses are restricted to a few monophyletic groups (i.e., clades). Most of these are amphibians and snakes, but a few rare origins (e.g., Pitohui birds) have stimulated research on acquired chemical defenses (Dumbacher et al. 1992 ). Selective pressures that lead to defense are usually associated with an organ- ism’s limited ability to escape predation or conspicuous behaviors and phenotypes that increase detectability by predators (e.g., diurnality or mating calls) (Speed and Ruxton 2005 ). Defended organisms frequently evolve warning signals to advertise their defense, a phenomenon known as aposematism (Mappes et al. 2005 ). Warning signals such as conspicuous coloration unambiguously inform predators that there will be a substantial cost if they proceed with attack or consumption of the defended prey (Mappes et al. 2005 ). However, aposematism is likely more complex than the simple pairing of signal and defense, encompassing a series of traits (i.e., the apose- matic syndrome) that alter morphology, physiology, and behavior (Mappes and J. C. Santos (*) Department of Zoology, Biodiversity Research Centre , University of British Columbia , #4200-6270 University Blvd , Vancouver , BC , Canada , V6T 1Z4 e-mail: [email protected] R. D. Tarvin University of Texas at Austin , 2415 Speedway Stop C0990 , Austin , TX 78712 , USA e-mail: [email protected] L.
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2007/0191272 A1 Stemmer Et Al
US 200701.91272A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0191272 A1 Stemmer et al. (43) Pub. Date: Aug. 16, 2007 (54) PROTEINACEOUS PHARMACEUTICALS Publication Classification AND USES THEREOF (76) Inventors: Willem P.C. Stemmer, Los Gatos, CA (51) Int. Cl. (US); Volker Schellenberger, Palo A6II 38/16 (2006.01) Alto, CA (US); Martin Bader, C40B 40/08 (2006.01) Mountain View, CA (US); Michael C40B 40/10 (2006.01) Scholle, Mountain View, CA (US) C07K I4/47 (2006.01) (52) U.S. Cl. ................. 514/12: 435/7.1: 435/6; 530/324 Correspondence Address: WILSON SONSN GOODRCH & ROSAT 650 PAGE MILL ROAD (57) ABSTRACT PALO ALTO, CA 94304-1050 (US) (21) Appl. No.: 11/528,927 The present invention provides cysteine-containing scaf folds and/or proteins, expression vectors, host cell and (22) Filed: Sep. 27, 2006 display systems harboring and/or expressing such cysteine containing products. The present invention also provides Related U.S. Application Data methods of designing libraries of Such products, methods of (60) Provisional application No. 60/721,270, filed on Sep. screening Such libraries to yield entities exhibiting binding 27, 2005. Provisional application No. 60/721,188, specificities towards a target molecule. Further provided by filed on Sep. 27, 2005. Provisional application No. the invention are pharmaceutical compositions comprising 60/743,622, filed on Mar. 21, 2006. the cysteine-containing products of the present invention. Patent Application Publication Aug. 16, 2007 Sheet 1 of 46 US 2007/0191272 A1 Takara togra: Patent Application Publication Aug. 16, 2007 Sheet 2 of 46 US 2007/0191272 A1 FIG.
[Show full text]